Ftse Mib
33.624,71
-0,42%
DAX
19.833,34
-0,42%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
95.420,61
0,33%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Zevra Therapeutics Inc (ZVRA) Zevra Therapeutics Inc (ZVRA) Notizie

Zevra Therapeutics Inc

ZVRA
8,49
0,00 (0,00%)
23 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/12/202413:30GLOBEZevra Therapeutics to be Added to Nasdaq Biotechnology Index..
06/12/202423:28EDGAR2Form 8-K - Current report
06/12/202423:00GLOBEZevra Therapeutics Announces Organizational Changes
26/11/202413:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
21/11/202422:51GLOBEZevra Therapeutics Announces U.S. Commercial Availability of..
14/11/202422:53EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
14/11/202419:00EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
13/11/202422:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:24EDGAR2Form 8-K - Current report
12/11/202422:05GLOBEZevra Therapeutics Reports Third Quarter 2024 Financial..
11/11/202422:36GLOBEZevra Therapeutics to Present Data Demonstrating Relevance..
06/11/202413:30GLOBEZevra Therapeutics to Participate at the Guggenheim..
31/10/202412:30GLOBEZevra Therapeutics to Report Third Quarter 2024 Financial..
16/10/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202413:30GLOBEZevra Therapeutics to Participate in Rare Disease Panel at..
09/10/202415:00GLOBENUCDF and Zevra Therapeutics Launch Check Ammonia Campaign..
24/9/202413:30GLOBEZevra Therapeutics to Present Top-Line Data from the Phase 2..
20/9/202422:12EDGAR2Form 8-K - Current report
20/9/202418:08GLOBEZevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S...
06/9/202414:30GLOBEZevra Therapeutics Presented New Data for Arimoclomol and..
29/8/202413:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
13/8/202422:17EDGAR2Form 8-K - Current report
13/8/202422:05GLOBEZevra Therapeutics Reports Second Quarter 2024 Financial..
13/8/202411:45IHMARKETNEWSU.S. Futures Climb Before Inflation Data; Oil Slips on OPEC..
09/8/202423:06EDGAR2Form 8-K - Current report
09/8/202422:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/8/202406:00GLOBEZevra Therapeutics Announces Pricing of Underwritten..
08/8/202422:09EDGAR2Form 8-K - Current report
08/8/202422:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/8/202422:01GLOBEZevra Therapeutics Announces Proposed Public Offering of..
07/8/202415:34GLOBEZevra Therapeutics to Present at Canaccord Genuity’s 44th..
02/8/202423:50GLOBEFDA Advisory Committee Votes Favorably that the Data Support..
30/7/202414:38GLOBEZevra Therapeutics to Report Second Quarter 2024 Financial..
17/7/202423:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/7/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/7/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202422:37EDGAR2Form 8-K - Current report
12/7/202422:23EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
09/7/202415:23EDGAR2Form 8-K - Current report
09/7/202415:00GLOBEZevra Announces FDA Advisory Committee Meeting to Review..
25/6/202413:30GLOBEZevra Therapeutics Expands Executive Leadership Team
18/6/202413:30PRNUSZevra Therapeutics Transitions to Orsini as the Specialty..
04/6/202423:13EDGAR2Form S-3 - Registration statement under Securities Act of..
03/6/202417:00GLOBEZevra Therapeutics Announces Positive Final Results from..
16/5/202403:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202403:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202403:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202403:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202403:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:47EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 8,49

La tua Cronologia

NASDAQ
ZVRA
Zevra Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network